mk-0616
merck
['cardio']
in a phase 2 trial, an oral #pcsk9 inhibitor lowered #ldl about the same amount observed with injectable pcsk9 inhibitors for 8 weeks #acc23 #cardiotwitter 
The content you need, when you need it.